Stroke RSS Page 9

Filtered By:
Specialty: Hematology
Source: Thrombosis Research

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 221 results found since Jan 2013.

Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?
Antiplatelet therapy is the cornerstone of secondary prevention against acute thrombotic events in patients with cardiovascular disease [1]. Health Organizations around the world recommend combination therapy with aspirin and a P2Y12 receptor inhibitor for up to one year following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), and lifelong aspirin therapy thereafter [2]. Vorapaxar, a first-in-class novel protease-activated receptor (PAR)-1 antagonist, was approved in addition to standard antiplatelet therapy, to further reduce the risk of myocardial infarction (MI), stroke, cardiovascular dea...
Source: Thrombosis Research - October 30, 2015 Category: Hematology Authors: Marie Lordkipanidzé Source Type: research

Arguments favoring low versus high dose aspirin in the prophylaxis of venous thromboembolism
The use of aspirin in the prevention of venous thromboembolism (VTE) is still controversial. In a profound review on the use of aspirin for primary and secondary prevention of venous thromboembolism and other cardiovascular disorders Cohen et al. [1] conclude that the benefits of aspirin are well documented for conditions like myocardial infarction, coronary heart disease, and stroke, but less clearly for prevention of VTE after orthopedic surgery. The latter indistinctness has been a matter of concern in many earlier reviews and meta-analyses, and has even led to non-uniform guidelines on VTE prevention from the American ...
Source: Thrombosis Research - January 27, 2016 Category: Hematology Authors: Piet Borgdorff, Geert Jan Tangelder Tags: Correspondence Source Type: research

Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study
Oral anticoagulants in patients with atrial fibrillation (AF) with moderate-to-high stroke risk are strongly recommended by the current guidelines.
Source: Thrombosis Research - February 23, 2016 Category: Hematology Authors: Natalia Mochalina, Anna Jöud, Maj Carlsson, Maria E.C. Sandberg, Anders Själander, Tord Juhlin, Peter J. Svensson Tags: Full Length Article Source Type: research

Association of von Willebrand factor deficiency with prevalent cardiovascular disease and asymptomatic carotid atherosclerosis: The Atherosclerosis Risk in Communities Study
Von Willebrand factor (VWF), a large multimeric glycoprotein, plays a critical role in hemostasis. It binds to subendothelial collagen at the site of vascular injury where it facilitates platelet activation. Given the role of VWF in platelet activation, and the role of platelets in cardiovascular events, such as myocardial infarction (MI) and ischemic stroke, VWF may influence the risk of cardiovascular disease (CVD). In addition, evidence suggests that VWF may affect CVD risk by playing a role in atherogenesis by direct participation in plaque formation [1].
Source: Thrombosis Research - May 31, 2016 Category: Hematology Authors: Craig D. Seaman, Kristen M. George, Margaret Ragni, Aaron R. Folsom Source Type: research

Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation
Multiple antithrombotic agents are available for stroke prevention in atrial fibrillation (AF). A decision aid can assist patients in making informed decisions that best serves their needs.Objective.To validate a decision aid to assist patients in choosing between antithrombotic agents (antiplatelets, warfarin, direct-acting oral anticoagulants (DOACs)) for AF.
Source: Thrombosis Research - June 14, 2016 Category: Hematology Authors: Safoora Fatima, Anne Holbrook, Sam Schulman, Steve Park, Sue Troyan, Greg Curnew Source Type: research

ABCB1 SNP rs4148738 Modulation of Apixaban Interindividual Variability
Direct Oral AntiCoagulants (DOACs) were approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF), for the prophylaxis of venous thromboembolism (VTE), in elective orthopaedic surgery, for treatment of acute VTE and prevention of recurrencies [1]. Apixaban is an orally active, direct selective factor Xa inhibitor [2,3].
Source: Thrombosis Research - July 11, 2016 Category: Hematology Authors: Claudia Dimatteo, Giovanna D'Andrea, Gennaro Vecchione, Oriana Paoletti, Giovanni Luca Tiscia, Rosa Santacroce, Michele Correale, Natale Brunetti, Elvira Grandone, Sophie Testa, Maurizio Margaglione Source Type: research

SePARating thrombosis and hemostasis?
Heart attack and ischemic stroke, which commonly arise from thrombotic occlusions, are the world-leading causes of death and a major health burden. In most cases, the rupture or erosion of an unstable atherosclerotic plaque, which results in the exposure of thrombogenic extracellular matrix proteins, triggers arterial thrombosis [14]. Under these conditions, platelets, which circulate in the blood stream, become captured and activated by extracellular matrix proteins. Inevitably, platelet activation leads to thrombus formation at sites of damage via the action of platelet integrins, predominantly αIIbβ3, and the presence...
Source: Thrombosis Research - July 20, 2016 Category: Hematology Authors: David Stegner Tags: Editorial Source Type: research

ABCB1 SNP rs4148738 modulation of apixaban interindividual variability
Direct Oral AntiCoagulants (DOACs) were approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF), for the prophylaxis of venous thromboembolism (VTE), in elective orthopaedic surgery, for treatment of acute VTE and prevention of recurrencies [1]. Apixaban is an orally active, direct selective factor Xa inhibitor [2,3].
Source: Thrombosis Research - July 11, 2016 Category: Hematology Authors: Claudia Dimatteo, Giovanna D'Andrea, Gennaro Vecchione, Oriana Paoletti, Giovanni Luca Tiscia, Rosa Santacroce, Michele Correale, Natale Brunetti, Elvira Grandone, Sophie Testa, Maurizio Margaglione Tags: Correspondence Source Type: research

Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation
Multiple antithrombotic agents are available for stroke prevention in atrial fibrillation (AF). A decision aid can assist patients in making informed decisions that best serves their needs.
Source: Thrombosis Research - June 14, 2016 Category: Hematology Authors: Safoora Fatima, Anne Holbrook, Sam Schulman, Steve Park, Sue Troyan, Greg Curnew Tags: Full Length Article Source Type: research

Clinical and laboratory predictors of deep vein thrombosis after acute stroke: Does D-dimer really improve predictive power?
We thank Kola and colleagues for their interest in our work titled ‘Clinical and laboratory predictors of deep vein thrombosis after acute stroke’ recently published in Thrombosis Research [1]. We are grateful for their thoughtful comments around the study methodology and data presentation [2].
Source: Thrombosis Research - August 11, 2016 Category: Hematology Authors: Ibrahim O. Balogun, Lara N. Roberts, Roopen Arya Tags: Correspondence Source Type: research

Platelet count is associated with cardiovascular disease, cancer and mortality: A population-based cohort study
Platelet count is used to determine bleeding risk and monitoring thrombopoiesis. While abnormal platelet counts are associated with mortality and morbidity, it is unclear whether it also apply to platelet counts within reference range.We investigated the relationship between platelet count (100 –450×109/L) and mortality, development of future cardiovascular disease (myocardial infarction, ischaemic stroke, or peripheral vascular disease), venous thromboembolism, bleeding or cancer in the general population.
Source: Thrombosis Research - August 20, 2016 Category: Hematology Authors: P.J. Vinholt, A.M. Hvas, H. Frederiksen, L. Bathum, M.K. J ørgensen, M. Nybo Source Type: research

Endothelial cell senescence and thrombosis: Ageing clots
Age is an important cardiovascular risk factor. Among others, age is associated with an increased risk to develop thrombotic cardiovascular complications, both in the arterial (acute myocardial infarction, stroke) and the venous (deep vein thrombosis, pulmonary embolism) system, which cannot be explained by the age-associated increase in cardiovascular risk factors alone. A number of studies have demonstrated that the accumulation of senescent endothelial cells and specific phenotypic and functional alterations associated with endothelial cell senescence may play an important role during the development and progression of ...
Source: Thrombosis Research - September 18, 2016 Category: Hematology Authors: Magdalena L. Bochenek, Eva Sch ütz, Katrin Schäfer Tags: Review Article Source Type: research

Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: Insight from its serial measurement
Patients with intracerebral hemorrhage during rivaroxaban treatment have small hematoma and favorable outcomes compared with those with warfarin. We investigated its possible mechanism, focusing on prothrombin fragment 1+2 (F1+2), a marker of thrombin generation.
Source: Thrombosis Research - October 12, 2016 Category: Hematology Authors: Joji Hagii, Hirofumi Tomita, Norifumi Metoki, Yoshiko Tamai, Shin Saito, Hiroshi Shiroto, Hiroyasu Hitomi, Takaatsu Kamada, Satoshi Seino, Koki Takahashi, Satoko Sasaki, Minoru Yasujima, Ken Okumura Tags: Full Length Article Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15